Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study
![](https://www.reumatismo.org/public/journals/1/cover_article_1028_en_US.jpg)
Submitted: 5 June 2017
Accepted: 17 December 2017
Published: 6 July 2018
Accepted: 17 December 2017
Abstract Views: 2077
PDF: 708
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- M. Filippini, C. Bazzani, S. Zingarelli, T. Ziglioli, M. Nuzzo, M. Vianelli, C. Biasini Rebaioli, R. Cattaneo, R. Gorla, Anti-TNFα agents in elderly patients with rheumatoid arthritis: a study of a group of 105 over sixty five years old patients , Reumatismo: Vol. 60 No. 1 (2008)
- R. Scrivo, F. Conti, F.R. Spinelli, S. Truglia, L. Magrini, M. Di Franco, F. Ceccarelli, G. Valesini, Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature , Reumatismo: Vol. 61 No. 2 (2009)
- E. Bartoloni Bocci, S. Marchesi, F. Delle Monache, G. Vaudo, A. Giordano, F. Ragni Alunni, C. Angrisani, E. Mannarino, Y. Shoenfeld, R. Gerli, Subclinical atherosclerosis in young patients with rheumatoid arthritis and low disease activity , Reumatismo: Vol. 57 No. 1 (2005)
- L. Degli Esposti, V. Perrone, D. Sangiorgi, L. Sinigaglia, Assessment of patients affected by rheumatoid arthritis eligible for biotechnological agents and evaluation of their healthcare resource utilization and related costs , Reumatismo: Vol. 73 No. 1 (2021)
- L. Punzi, M. Matucci Cerinic, F. Cantini, G. Bagnato, U. Fiocco, C. Ferri, S. Bombardieri, Treatment patterns of snti-TNF agents in Italy: an observational study , Reumatismo: Vol. 63 No. 1 (2011)
- A. Iagnocco, C. Perella, F. Ceccarelli, E. Tripodo, C. Alessandri, L. Magrini, G. Valesini, Ultrasonographic assessment of the response to Etanercept treatment in patients with rheumatoid arthritis , Reumatismo: Vol. 58 No. 3 (2006)
- M. Gutierrez, E. Filippucci, L. Bugatti, C. Bertolazzi, W. Grassi, Severe drug hypersensitivity syndrome due to sulphasalazine in patient with rheumatoid arthritis , Reumatismo: Vol. 61 No. 1 (2009)
- F. Salaffi, A. Stancati, Disability and quality of life of patients with rheumatoid arthritis: assessment and perspectives , Reumatismo: Vol. 56 No. s1 (2004)
- G. Pasero, P. Marson, short history of anti-rheumatic therapy. IV. Corticosteroids , Reumatismo: Vol. 62 No. 4 (2010)
- G. Carlino, M. Fornaro, L. Santo, R. Bucci, A. Semeraro, L. Quarta, F. D'Onofrio, A. Marsico, C. Zuccaro, P.C. Falappone, D. Mazzotta, F.P. Cantatore, M. Muratore, F. Iannone, Occult HBV infection may negatively impact on drug survival in patients with rheumatoid arthritis on treatment with a first biologic drug. An appraisal from the Biologic Apulian Registry (BIOPURE) , Reumatismo: Vol. 71 No. 1 (2019)
<< < 10 11 12 13 14 15 16 17 18 19 > >>
You may also start an advanced similarity search for this article.